11ª edição

New data from CheckMate 649 suggest that adding nivolumab to chemotherapy to treat advanced metastatic or unresectable disease improves prognosis

per: Grupo Oncoclínicas
New data from CheckMate 649 suggest that adding nivolumab to chemotherapy to treat advanced metastatic or unresectable disease improves prognosis

Scientific commission

Alexandre Jácome
Alexandre Jácome
Alexandre Palladino
Alexandre Palladino
Gabriel Prolla
Gabriel Prolla
Roberto Gil
Roberto Gil

Contributors

Noelle Suemi Wassano Nakayama
Noelle Suemi Wassano Nakayama

The Phase III, randomized, multicenter, open-label, CheckMate 649 study compared nivolumab in combination with platinum fluoropyrimidine-based chemotherapy versus chemotherapy alone in treatment-naïve subjects with advanced/metastatic gastric or esophagogastric cancer. HER-2 positive individuals were excluded.

“It was the first study that showed an overall survival greater than one year in patients with HER-2 negative advanced gastric adenocarcinoma”, comments clinical oncologist at the Institute of Hematology and Oncology of Curitiba (IHOC), clinic of Grupo Oncoclínicas, Noelle Suemi. Wassan.

At minimum 12-month follow-up for 1581 randomized patients, the combination of nivolumab + chemotherapy had a statistically significant overall survival benefit versus chemotherapy in all patients. A progression-free survival benefit was also observed, with a 23% lower chance of recurrence in patients who received nivolumab.

Access our website and read the full article with all the details of this study.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L